KNSA vs. GEV
KNSA (Kiniksa Pharmaceuticals, Ltd.) and GEV (GE Vernova Inc.) are both stocks. KNSA operates in Biotechnology (Healthcare), while GEV operates in Specialty Industrial Machinery (Industrials). Over the past year, KNSA returned 145.67% vs 50.32% for GEV. Their 0.15 correlation means their historical movements had little consistent relationship.
Performance
KNSA vs. GEV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 80.22% return, which is significantly higher than GEV's 51.80% return.
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
GEV
- 1D
- 0.85%
- 1M
- -12.70%
- 6M
- 36.49%
- YTD
- 51.80%
- 1Y
- 50.32%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 151.05%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $3.36B | $3.09B | $2.94B | |
| $68.75M | $54.52M | $46.86M |
KNSA vs. GEV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | -0.95% |
GEV GE Vernova Inc. | 51.80% | 99.02% | 186.24% |
Correlation
The correlation between KNSA and GEV is 0.07, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.07 |
Correlation (All Time) Calculated using the full available price history since Mar 27, 2024 | 0.15 |
Fundamentals
KNSA:
$5.67B
GEV:
$263.75B
KNSA:
$1.00
GEV:
$34.87
KNSA:
74.38
GEV:
28.40
KNSA:
0.72
GEV:
0.13
KNSA:
7.14
GEV:
6.54
KNSA:
9.48
GEV:
22.36
KNSA:
$840.85M
GEV:
$41.37B
KNSA:
$546.22M
GEV:
$8.36B
KNSA:
$111.62M
GEV:
$8.66B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. GEV — Risk / Return Rank
KNSA
GEV
KNSA vs. GEV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and GE Vernova Inc. (GEV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KNSA | GEV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.97 | ||
| Sortino ratioReturn per unit of downside risk | +2.54 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.20 | +0.32 |
| Calmar ratioReturn relative to maximum drawdown | 6.94 | 2.06 | +4.88 |
| Martin ratioReturn relative to average drawdown | 24.13 | 5.48 | +18.65 |
Loading charts...
Drawdowns
KNSA vs. GEV - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, which is greater than GEV's maximum drawdown of -38.29%. Use the drawdown chart below to compare losses from any high point for KNSA and GEV.
Loading charts...
Drawdown Indicators
| KNSA | GEV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -38.29% | -44.77% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -24.57% | +3.45% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | — | — |
Current DrawdownCurrent decline from peak | -8.13% | -15.71% | +7.58% |
Average DrawdownAverage peak-to-trough decline | -40.09% | -7.15% | -32.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.06% | 9.22% | -3.16% |
Volatility
KNSA vs. GEV - Volatility Comparison
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a higher volatility of 26.47% compared to GE Vernova Inc. (GEV) at 18.64%. This indicates that KNSA's price experiences larger fluctuations and is considered to be riskier than GEV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | GEV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.47% | 18.64% | +7.83% |
Volatility (6M)Calculated over the trailing 6-month period | 41.55% | 38.47% | +3.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.77% | 51.98% | -2.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.77% | 54.55% | +0.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.34% | 54.55% | +9.79% |
Dividends
KNSA vs. GEV - Dividend Comparison
KNSA has not paid dividends to shareholders, while GEV's dividend yield for the trailing twelve months is around 0.18%.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
GEV GE Vernova Inc. | 0.18% | 0.11% | 0.08% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 0.00% | 0.00% | 0.00% |
Financials
KNSA vs. GEV - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and GE Vernova Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. GEV - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
GEV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, GE Vernova Inc. reported a gross profit of 2.36B and revenue of 11.10B. Therefore, the gross margin over that period was 21.3%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
GEV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, GE Vernova Inc. reported an operating income of 655.00M and revenue of 11.10B, resulting in an operating margin of 5.9%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
GEV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, GE Vernova Inc. reported a net income of 668.00M and revenue of 11.10B, resulting in a net margin of 6.0%.
Frequently Asked Questions
KNSA and GEV have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (26.47%) compared to GEV (18.64%). In terms of maximum drawdown, KNSA dropped -83.06% vs GEV's -38.29%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 0.97), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and GEV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer